Scynexis gets BARDA award worth up to $214 million for antifungal SCY-247

Scynexis announced on September 28, 2026 that it had signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support development of SCY-247, described as the Company's second-generation fungerp antifungal candidate¹. The agreement was executed on September 25, 2026, according to the company's 8-K filing.

The BARDA Contract provides for potential total non-dilutive funding by BARDA of up to $214 million.¹ The initial base period commences in September 2026 and provides approximately $18.5 million¹ to move both oral and intravenous forms of the drug forward for patients with invasive candidiasis. The remainder of the award depends on BARDA exercising up to six options, which could extend the contract term for up to ten years.¹ Scynexis said that if every option is exercised, the funding could support SCY-247's development from its current stage all the way to New Drug Application filings covering two uses: treating invasive candidiasis and preventing invasive fungal infections in high-risk patients.

The award is structured as a cost-share arrangement, with BARDA covering eligible SCY-247 costs including both direct and general and administrative expenses.¹ Scynexis said it expects to fund its portion of near-term program costs within its existing operating plan, and that development plans for SCY-770, its ADPKD candidate, along with its cash runway into 2029, remain unchanged.¹

On the science, Scynexis noted that SCY-247 has been granted Orphan, Qualified Infectious Disease Product and Fast Track designations by the FDA.¹ The company reported that oral-formulation dosing results were released in September 2025, while testing of the intravenous version has finished its dosing stage with data review still underway, per the filing.